RxDoctor Payments Data

Jay Yepuri, MD

Gastroenterology · Bedford, TXNPI 1811007883

Payments from drug & device makers

$406,627in general payments, 2019–2025

Across 1,214 payments — averaging $334.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$124K
  • AbbVie$107K
  • Phathom Pharmaceuticals, Inc.$78K
  • Regeneron Healthcare Solutions, Inc.$42K
  • Conmed Corporation$7K
  • Boston Scientific$6K
  • plus $42K from 53 others
$1,313in research payments, 2019–2025

Across 1 payment — averaging $1312.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Consulting fees$27,3537%
  • Speaking & faculty fees$297,14873%
  • Travel & lodging$53,13113%
  • Food & beverage$28,8647%
  • Education$430%
  • Gifts$720%
  • Entertainment$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi123$124,427
AbbVie(2 entities)388$106,709
Phathom Pharmaceuticals, Inc.101$78,065
Regeneron Healthcare Solutions, Inc.83$41,884
Conmed Corporation21$7,322
Boston Scientific69$6,044
Redhill Biopharma Inc.17$5,888
Pfizer18$5,585
Covidien LP15$4,242
Amgen16$3,784
Anx Robotica Corp4$3,773
Medtronic8$3,762
Gastrogpo, LLC6$2,128
Ambu Inc.25$2,069
Boehringer Ingelheim2$1,855
Iterative Scopes, Inc.8$1,004
Johnson & Johnson(2 entities)49$812
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC49$741
Enterra Medical, Inc.6$573
AstraZeneca1$537
Takeda Pharmaceuticals U.S.A., Inc.29$526
Shire North American Group Inc1$500
Neuraxis, Inc.2$384
GI Supply, Inc.1$375
Bristol Myers Squibb45$364
QOL Medical, LLC11$291
3-d Matrix, Inc.1$268
Janssen Scientific Affairs, LLC3$260
Lilly USA, LLC13$228
Ardelyx, Inc.10$193
Axonics, Inc.2$183
E.r. Squibb & Sons, L.L.C.4$174
Endogastric Solutions, Inc5$159
Ironwood Pharmaceuticals, Inc11$156
Lucid Diagnostics Inc.1$130
Braintree Laboratories, Inc.4$122
Merck7$102
Echosens North America, Inc.3$96
Shionogi Inc4$81
Organon10$77
Madrigal Pharmaceuticals4$76
ERBE USA Inc1$71
Lumendi LLC1$68
Alnylam Pharmaceuticals Inc.3$56
Celltrion USA Inc.3$48
Nestle Healthcare Nutrition Inc.3$46
Evoke Pharma, Inc.3$45
Aimmune Therapeutics, Inc.3$44
Daiichi Sankyo Inc.3$41
Mallinckrodt Hospital Products Inc.2$39
Olympus America Inc.1$38
Mauna Kea Technologies, Inc.1$29
Intercept Pharmaceuticals, Inc.2$28
AMAG Pharmaceuticals, Inc.2$27
Novo Nordisk1$26
Vivus LLC2$24
Laborie Medical Technologies Corp.1$18
Ferring Pharmaceuticals Inc.1$14
Fresenius Kabi USA, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406,627 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$163,819
Medicare patients
394
Services billed
2,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZeposiaOzanimod Hydrochloride13$109,474
LinzessLinaclotide37$42,091
CreonLipase/Protease/Amylase11$17,107
SutabSod Sulf/Pot Chloride/Mag Sulf83$13,620
Mesalamine17$9,419
Omeprazole277$5,887
Sucralfate61$3,017
ClenpiqSod Picosulf/Mag Ox/Citric Ac17$2,697
Pantoprazole Sodium153$2,135
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag13$1,632
Esomeprazole Magnesium26$1,083
Dicyclomine Hcl42$949
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine20$853
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Zeposia$174$109,47413 claims
AbbVieLinzess, Creon$106,709$59,19948 claims
Braintree Laboratories, Inc.Sutab, Suflave$122$15,25296 claims
Ferring Pharmaceuticals Inc.Clenpiq$14$2,69717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →